Insights from molecular pathways: Potential pharmacologic targets of benign thyroid nodules

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 14, Issue 5, 2007, Pages 393-397

  Eszlinger, Markus ^a   Jaeschke, Holger ^a   Paschke, Ralf ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Cold thyroid nodule; G protein signaling; Hot thyroid nodule; Microarray; Thyrotropin receptor agonist

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; IODINE; PROTEIN KINASE; PROTEIN KINASE C; THYROGLOBULIN; THYROTROPIN RECEPTOR; THYROTROPIN RECEPTOR AGONIST; UNCLASSIFIED DRUG;

CELL PROLIFERATION; DRUG TARGETING; GRAVES DISEASE; HORMONE SYNTHESIS; IN VITRO STUDY; IODINE DEFICIENCY; MICROARRAY ANALYSIS; MOLECULAR WEIGHT; MUTAGENESIS; NONHUMAN; OXIDATIVE STRESS; REVIEW; THYROID NODULE;

ADENOCARCINOMA, FOLLICULAR; GRAVES DISEASE; GTP-BINDING PROTEIN ALPHA SUBUNITS, GQ-G11; HUMANS; MOLECULAR WEIGHT; MUTATION; OXIDATIVE STRESS; PROTEIN KINASE C; RECEPTORS, THYROTROPIN; SIGNAL TRANSDUCTION; SYMPORTERS; THYROGLOBULIN; THYROID NEOPLASMS; THYROID NODULE;

EID: 34548382994     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e3282ef5f96     Document Type: Review

References (64)

1. Volzke H, Ludemann J, Robinson DM, et al. The prevalence of undiagnosed thyroid disorders in a previously iodine-deficient area. Thyroid 2003; 13:803-810.
2. Belfiore A, La Rosa GL, La Porta GA, et al. Cancer risk in patients with cold thyroid nodules: relevance of iodine intake, sex, age, and multinodularity. Am J Med 1992; 93:363-369.
3. Knudsen N, Perrild H, Christiansen E, et al. Thyroid structure and size and two-year follow-up of solitary cold thyroid nodules in an unselected population with borderline iodine deficiency. Eur J Endocrinol 2000; 142:224-230.
4. Zelmanovitz F, Genro S, Gross JL. Suppressive therapy with levothyroxine for solitary thyroid nodules: a double-blind controlled clinical study and cumulative meta-analyses. J Clin Endocrinol Metab 1998; 83:3881-3885.
5. Parma J, Duprez L, Van Sande J, et al. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 1993; 365:649-651.
6. Lyons J, Landis CA, Harsh G, et al. Two G protein oncogenes in human endocrine tumors. Science 1990; 249:655-659.
7. Paschke R, Ludgate M. The thyrotropin receptor in thyroid diseases. N Engl J Med 1997; 337:1675-1681.
8. Neumann S, Schuchardt K, Reske A, et al. Lack of correlation for sodium iodide symporter mRNA and protein expression and analysis of sodium iodide symporter promoter methylation in benign cold thyroid nodules. Thyroid 2004; 14:99-111.
9. Eszlinger M, Krohn K, Berger K, et al. Gene expression analysis reveals evidence for increased expression of cell cycle-associated genes and Gq-protein-protein kinase C signaling in cold thyroid nodules. J Clin Endocrinol Metab 2005; 90:1163-1170.
10. Maier J, Van Steeg H, Van Oostrom C, et al. Deoxyribonucleic acid damage and spontaneous mutagenesis in the thyroid gland of rats and mice. Endocrinology 2006; 147:3391-3397. This paper outlines a strikingly high mutation rate due to oxidative DNA damage in the thyroid.
11. Maier J, Van Steeg H, Van Oostrom C, et al. Iodine deficiency activates antioxidant genes and causes DNA damage in the thyroid gland of rats and mice. Biochim Biophys Acta; 2007. in press.
12. 2 detoxification.
13. Führer D, Holzapfel HP, Wonerow P, et al. Somatic mutations in the thyrotropin receptor gene and not in the Gs alpha protein gene in 31 toxic thyroid nodules. J Clin Endocrinol Metab 1997; 82:3885-3891.
14. O'Sullivan C, Barton CM, Staddon SL, et al. Activating point mutations of the gsp oncogene in human thyroid adenomas. Mol Carcinog 1991; 4:345-349.
15. Parma J, Duprez L, Van Sande J, et al. Diversity and prevalence of somatic mutations in the thyrotropin receptor and Gs alpha genes as a cause of toxic thyroid adenomas. J Clin Endocrinol Metab 1997; 82:2695-2701.
16. Paschke R, Tonacchera M, Van Sande J, et al. Identification and functional characterization of two new somatic mutations causing constitutive activation of the thyrotropin receptor in hyperfunctioning autonomous adenomas of the thyroid. J Clin Endocrinol Metab 1994; 79:1785-1789.
17. Porcellini A, Ciullo I, Laviola L, et al. Novel mutations of thyrotropin receptor gene in thyroid hyperfunctioning adenomas. Rapid identification by fine needle aspiration biopsy. J Clin Endocrinol Metab 1994; 79:657-661.
18. Russo D, Arturi F, Wicker R, et al. Genetic alterations in thyroid hyperfunctioning adenomas. J Clin Endocrinol Metab 1995; 80:1347-1351.
19. Russo D, Arturi F, Suarez HG, et al. Thyrotropin receptor gene alterations in thyroid hyperfunctioning adenomas. J Clin Endocrinol Metab 1996; 81:1548-1551.
20. Vanvooren V, Uchino S, Duprez L, et al. Oncogenic mutations in the thyrotropin receptor of autonomously functioning thyroid nodules in the Japanese population. Eur J Endocrinol 2002; 147:287-291.
21. Trülzsch B, Krohn K, Wonerow P, et al. Detection of thyroid-stimulating hormone receptor and Gsalpha mutations: in 75 toxic thyroid nodules by denaturing gradient gel electrophoresis. J Mol Med 2001; 78:684-691.
22. Gozu HI, Bircan R, Krohn K, et al. Similar prevalence of somatic TSH receptor and Gsalpha mutations in toxic thyroid nodules in geographical regions with different iodine supply in Turkey. Eur J Endocrinol 2006; 155:535-545.
23. Krohn K, Paschke R. Progress in understanding the etiology of thyroid autonomy. J Clin Endocrinol Metab 2001; 86:3336-3345.
24. Eszlinger M, Krohn K, Frenzel R, et al. Gene expression analysis reveals evidence for inactivation of the TGF-beta signaling cascade in autonomously functioning thyroid nodules. Oncogene 2004; 23:795-804.
25. Arturi F, Scarpelli D, Coco A, et al. Thyrotropin receptor mutations and thyroid hyperfunctioning adenomas ten years after their first discovery: unresolved questions. Thyroid 2003; 13:341-343.
26. Führer D, Mix M, Wonerow P, et al. Variable phenotype associated with Ser505Asn-activating thyrotropin-receptor germline mutation. Thyroid 1999; 9:757-761.
27. Wattel S, Mircescu H, Venet D, et al. Gene expression in thyroid autonomous adenomas provides insight into their physiopathology. Oncogene 2005; 24:6902-6916.
28. Eszlinger M, Krohn K, Beck M, et al. Comparison of differential gene expression of hot and cold thyroid nodules with primary epithelial cell culture models by investigation of co-regulated gene sets. Biochim Biophys Acta 2006; 1763:263-271.
29. Van Staveren WC, Solis DW, Delys L, et al. Gene expression in human thyrocytes and autonomous adenomas reveals suppression of negative feedbacks in tumorigenesis. Proc Natl Acad Sci U S A 2006; 103:413-418. This paper shows differences in the gene expression of different negative feedback modulators of the cAMP cascade, suggesting a loss of negative feedback control in the tumors by comparing gene expression data of HTNs and thyrotropin- stimulated primary cultures.
30. Persani L, Lania A, Alberti L, et al. Induction of specific phosphodiesterase isoforms by constitutive activation of the cAMP pathway in autonomous thyroid adenomas. J Clin Endocrinol Metab 2000; 85:2872-2878.
31. Voigt C, Holzapfel HP, Meyer S, Paschke R. Increased expression of G-protein-coupled receptor kinases 3 and 4 in hyperfunctioning thyroid nodules. J Endocrinol 2004; 182:173-182.
32. Eszlinger M, Holzapfel HP, Voigt C, et al. RGS 2 expression is regulated by TSH and inhibits TSH receptor signaling. Eur J Endocrinol 2004; 151:383-390.
33. Tonjes A, Miedlich S, Holzapfel HP, et al. Expression of regulators of G protein signaling mRNA is differentially regulated in hot and cold thyroid nodules. Thyroid 2004; 14:896-901.
34. Oda Y, Sanders J, Roberts S, et al. Analysis of carbohydrate residues on recombinant human thyrotropin receptor. J Clin Endocrinol Metab 1999; 84:2119-2125.
35. Frenzel R, Krohn K, Eszlinger M, et al. Sialylation of human thyrotropin receptor improves and prolongs its cell-surface expression. Mol Pharmacol 2005; 68:1106-1113.
36. Eszlinger M, Krohn K, Kratzsch J, et al. Growth factor expression in cold and hot thyroid nodules. Thyroid 2001; 11:125-135.
37. Voigt C, Holzapfel H, Paschke R. Expression of beta-arrestins in toxic and cold thyroid nodules. FEBS Lett 2000; 486:208-212.
38. Chen W, Kirkbride KC, How T, et al. Beta-arrestin 2 mediates endocytosis of type III TGF-beta receptor and down-regulation of its signaling. Science 2003; 301:1394-1397.
39. Van Straten NC, Schoonus-Gerritsma GG, Van Someren RG, et al. The first orally active low molecular weight agonists for the LH receptor: thienopyr(im)idines with therapeutic potential for ovulation induction. Chembiochem 2002; 3:1023-1026.
40. Jaschke H, Neumann S, Moore S, et al. A low molecular weight agonist signals by binding to the transmembrane domain of thyroid-stimulating hormone receptor (TSHR) and luteinizing hormone/chorionic gonadotropin receptor (LHCGR). J Biol Chem 2006; 281:9841-9844. This paper shows that in contrast to the ectodomain binding of cognate ligands, LMW agonists can bind to and activate glycoprotein hormone receptors also via interaction with their transmembrane domain.
41. Sobrinho-Simoes M, Preto A, Rocha AS, et al. Molecular pathology of well differentiated thyroid carcinomas. Virchows Arch 2005; 447:787-793.
42. DeLellis RA. Pathology and genetics of thyroid carcinoma. J Surg Oncol 2006; 94:662-669. This paper reviews the molecular pathology of thyroid carcinoma, such as follicular, papillary, anaplastic and medullary thyroid carcinoma.
43. Joba W, Spitzweg C, Schriever K, Heufelder AE. Analysis of human sodium/ iodide symporter, thyroid transcription factor-1, and paired-box-protein-8 gene expression in benign thyroid diseases. Thyroid 1999; 9:455-466.
44. - symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J Clin Endocrinol Metab 1999; 84:3228-3234.
45. Russo D, Bulotta S, Bruno R, et al. Sodium/iodide symporter (NIS) and pendrin are expressed differently in hot and cold nodules of thyroid toxic multinodular goiter. Eur J Endocrinol 2001; 145:591-597.
46. Dohan O, De la Vieja A, Paroder V, et al. The sodium/iodide symporter (NIS): characterization, regulation, and medical significance. Endocr Rev 2003; 24:48-77.
47. - symporter (NIS) in a large sampling of thyroid cancer cases. J Clin Endocrinol Metab 2001; 86:2697-2700.
48. Bachrach LK, Eggo MC, Mak WW, Burrow GN. Phorbol esters stimulate growth and inhibit differentiation in cultured thyroid cells. Endocrinology 1985; 116:1603-1609.
49. Haye B, Aublin JL, Champion S, et al. Tetradecanoyl phorbol-13-acetate counteracts the responsiveness of cultured thyroid cells to thyrotropin. Biochem Pharmacol 1985; 34:3795-3802.
50. Roger PP, Reuse S, Servais P, et al. Stimulation of cell proliferation and inhibition of differentiation expression by tumor-promoting phorbol esters in dog thyroid cells in primary culture. Cancer Res 1986; 46:898-906.
51. Takasu N, Shimizu Y, Yamada T. Tumour promoter 12-O-tetradecanoylphorbol 13-acetate and epidermal growth factor stimulate proliferation and inhibit differentiation of porcine thyroid cells in primary culture. J Endocrinol 1987; 113:485-487.
52. Vassart G, Dumont JE. The thyrotropin receptor and the regulation of thyrocyte function and growth. Endocr Rev 1992; 13:596-611.
53. Berridge MJ. Inositol trisphosphate and calcium signaling. Nature 1993; 361:315-325.
54. Krohn K, Stricker I, Emmrich P, Paschke R. Cold thyroid nodules show a marked increase in proliferation markers. Thyroid 2003; 13:569-575.
55. Krohn K, Emmrich P, Ott N, Paschke R. Increased thyroid epithelial cell proliferation in toxic thyroid nodules. Thyroid 1999; 9:241-246.
56. Esapa CT, Johnson SJ, Kendall-Taylor P, et al. Prevalence of Ras mutations in thyroid neoplasia. Clin Endocrinol (Oxf) 1999; 50:529-535.
57. Krohn K, Reske A, Ackermann F, et al. Ras mutations are rare in solitary cold and toxic thyroid nodules. Clin Endocrinol (Oxf) 2001; 55:241-248.
58. Gire V, Wynford-Thomas D. RAS oncogene activation induces proliferation in normal human thyroid epithelial cells without loss of differentiation. Oncogene 2000; 19:737-744.
59. Eszlinger M, Wiench M, Jarzab B, et al. Meta- and reanalysis of gene expression profiles of hot and cold thyroid nodules and papillary thyroid carcinoma for gene groups. J Clin Endocrinol Metab 2006; 91:1934-1942.
60. Ciampi R, Knauf JA, Kerler R, et al. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest 2005; 115:94-101.
61. Frattini M, Ferrario C, Bressan P, et al. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 2004; 23:7436-7440.
62. Kimura ET, Nikiforova MN, Zhu Z, et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003; 63:1454-1457.
63. Soares P, Trovisco V, Rocha AS, et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 2003; 22:4578-4580.
64. Melillo RM, Castellone MD, Guarino V, et al. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest 2005; 115:1068-1081.